June 2024 in “British Journal of Dermatology” Alopecia areata greatly affects quality of life, especially mental health, and newer assessment tools better capture this impact than older ones.
April 2024 in “Frontiers in pharmacology” Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
March 2024 in “Clinical and experimental dermatology” Topical corticosteroids may be a safe and effective treatment for severe alopecia areata in children.
January 2024 in “Medicine” Hypothyroidism is often linked to the hair loss condition telogen effluvium.
January 2024 in “Skin appendage disorders” Using growth factors and microneedling shows promise for hair regrowth in Alopecia Areata, but more research is needed.
Reducing the dose of Baricitinib to 2mg still helped over half of the patients with severe scalp alopecia maintain their hair regrowth after two years.
August 2023 in “Skin Research and Technology” Measuring bald patch size can help grade hair loss severity, with photograph-based evaluation being more reliable.
January 2023 in “Przegla̧d dermatologiczny” There are two main types of alopecia areata with different severity, and diagnosis is made through clinical examination and trichoscopy, influencing treatment choices.
September 2022 in “Intisasi sains media” A young child with complete hair loss improved significantly with a combination of hair growth treatments and laser therapy.
July 2022 in “Journal of Investigative Dermatology” The conclusion suggests that a new system for measuring hair loss could be created using automated analysis of photographs.
June 2022 in “Frontiers in Immunology” Tofacitinib regrew hair in a man with total hair loss but raised cytokine levels, needing more research on possible side effects.
July 2021 in “Dermatology archives” Methotrexate may effectively and safely treat hair loss in children, with notable improvement after 12-15 months.
January 2021 in “International journal of basic and clinical pharmacology” Hydroxychloroquine is less effective than betamethasone oral mini pulse therapy for treating alopecia areata.
Topical calcipotriol successfully treated hair loss in three patients with Alopecia Totalis.
April 2018 in “Journal of Investigative Dermatology” Both Th1 and Th2 immune responses are increased in alopecia areata, with Th2 response more strongly linked to how severe the disease is.
January 2018 in “Journal of the American Academy of Dermatology” Combining pulsed prednisone with tofacitinib can lead to lasting hair regrowth in severe alopecia areata patients.
Testosterone raises blood pressure by affecting kidney function and brain gene regulation over time.
Anionic surfactants significantly improve the foaming of minoxidil gel shampoo.
February 2011 in “Annales de dermatologie et de vénéréologie” Tofacitinib shows promise for treating severe alopecia areata with good safety and effectiveness.
April 2026 in “Dermatology and Therapy” Baricitinib 4 mg should be used for at least 1 year to see significant hair regrowth in severe alopecia areata.
STS01 1% effectively promotes hair regrowth with minimal side effects.
Centralized imaging provides more accurate and consistent hair loss measurements in alopecia areata.
March 2026 in “International Journal of Dermatology and Venereology” Abrocitinib significantly improved hair regrowth in adolescents with alopecia areata without serious safety issues.
March 2026 in “Mendeley Data” Janus kinase inhibitors help hair regrowth in kids with alopecia areata but need more safety research.
March 2026 in “Mendeley Data” Janus kinase inhibitors can help children with alopecia areata regrow hair but may have some risks.
March 2026 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is being tested for safety and effectiveness in young children with severe alopecia areata.
March 2026 in “Clinical Cosmetic and Investigational Dermatology” Rituximab can cause skin issues, but baricitinib may help improve them.
March 2026 in “The American Journal of Managed Care” JAK inhibitors can help treat alopecia areata but have risks and high costs.
March 2026 in “SHILAP Revista de lepidopterología” Rituximab may cause skin issues, but baricitinib can help improve them.
March 2026 in “Clinical Cosmetic and Investigational Dermatology” Upadacitinib improved multiple immune-related conditions in one patient.